HSBC Holdings
ALLO icon

HSBC Holdings’s Allogene Therapeutics ALLO Stock Holding History

HSBC Holdings’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$638K Buy
260,404
+112,268
+76% +$225K ﹤0.01% 2099
2025
Q4 		$199K Buy
148,136
+54,071
+57% +$71.3K ﹤0.01% 2692
2025
Q3 		$114K Sell
94,065
-4,426
-4% -$5.28K ﹤0.01% 2581
2025
Q2 		$115K Buy
98,491
+17,056
+21% +$22.7K ﹤0.01% 2823
2025
Q1 		$115K Buy
81,435
+12,280
+18% +$23.2K ﹤0.01% 2778
2024
Q4 		$147K Buy
69,155
+16,768
+32% +$41.4K ﹤0.01% 2803
2024
Q3 		$148K Buy
52,387
+7,723
+17% +$20.6K ﹤0.01% 2716
2024
Q2 		$103K Sell
44,664
-9,452
-17% -$27.9K ﹤0.01% 2722
2024
Q1 		$242K Buy
54,116
+9,452
+21% +$39.4K ﹤0.01% 2571
2023
Q4 		$142K Buy
44,664
+28,509
+176% +$80.9K ﹤0.01% 2537
2023
Q3 		$50.7K Buy
+16,155
New +$70.8K ﹤0.01% 2626
2022
Q3 		– Sell
-11,500
Closed -$131K – 2907
2022
Q2 		$131K Sell
11,500
-16,929
-60% -$150K ﹤0.01% 2989
2022
Q1 		$261K Buy
28,429
+11,680
+70% +$122K ﹤0.01% 2842
2021
Q4 		$251K Sell
16,749
-10,318
-38% -$182K ﹤0.01% 2902
2021
Q3 		$698K Sell
27,067
-15,393
-36% -$365K ﹤0.01% 2069
2021
Q2 		$1.11M Buy
42,460
+30,960
+269% +$883K ﹤0.01% 1715
2021
Q1 		$406K Sell
11,500
-4,110
-26% -$139K ﹤0.01% 2126
2020
Q4 		$395K Sell
15,610
-1,156
-7% -$37.7K ﹤0.01% 2357
2020
Q3 		$634K Buy
16,766
+5,266
+46% +$199K ﹤0.01% 1786
2020
Q2 		$492K Sell
11,500
-1,439
-11% -$52K ﹤0.01% 1844
2020
Q1 		$245K Buy
+12,939
New +$308K ﹤0.01% 2172

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's ALLO Position: Q1 2026 in Review

HSBC Holdings increased its Allogene Therapeutics (ALLO) stake by 76% in Q1 2026, buying an estimated $225K and bringing the position to 260,404 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

HSBC Holdings first reported a position in ALLO in Q1 2020 and has held it in 21 quarters since. The position peaked at $1.11M in Q2 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • HSBC Holdings held 260,404 shares of Allogene Therapeutics worth $638K as of Q1 2026.
  • HSBC Holdings bought 112,268 Allogene Therapeutics shares in Q1 2026, an estimated $225K.
  • Allogene Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2099 holding.
  • HSBC Holdings first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • HSBC Holdings's Allogene Therapeutics position peaked at $1.11M in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.